



ABIVAX to participate in the upcoming Jefferies Global Healthcare Conference in London and the German Equity Forum in Frankfurt

November 12, 2015

Paris, France November 12, 2015 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral and vaccine therapies for diseases like HIV/AIDS and the hepatitis B virus (HBV), today announced that its CEO, Prof. Dr. Hartmut Ehrlich will participate in the Jefferies 2015 Global Healthcare Conference in London on November 18 and 19, 2015.

[Download as a pdf](#)